Publications

Melbourne Prostate Institute Publications

William SG, Millar JL, Duchesne GM, Dally MJ, Royce PL, Snow RM, Factors predicting for urinary morbidity following 125-iodine transperineal prostate brachytherapy.  Radiotherapy and Oncology. 2004;73:33-38.

Williams SG, Duchesne GM, Millar JL, Pratt GR, Both pretreatment prostate-specific antigen level and post-treatment biochemical failure are independent predictors of overall survival following radiotherapy for prostate cancer.  International Journal of Radiation Oncology, Biology and Physics. 2004;60(4)1082-1087.

Williams SG, Millar JL, Dally MJ, Sia S, Miles W, Duchesne GM, What defines intermediate-risk prostate cancer?  Variability in published prognostic models. International Journal of Radiation Oncology, Biology and Physics. 2004;58(1):11-18.

Gorman L, Millar J, Dally M, Pulsed dose rate Brachytherapy (PDRB) as salvage for locally recurrent prostate cancer following definitive external beam radiotherapy (EBRT) to the prostate. Australasian Radiology. 2006;50:A66.

Millar JL, Longano AZ, Imbert SJ, Stokes D, A simple technique for determining accurate urethral dosimetry after seed brachytherapy for prostate cancer. Brachytherapy. 2006;5(1):27.

Millar JL, Obeysekara L, Brown T, Lord L, Brown M, “Whereas I was blind, but now I see[d]“…calculating prostate external beam treatment margins from daily portal imaging of implanted gold seed movement. Australasian Radiology. 2006;50:A64.

Shaw MG, Crosbie J, Millar JL, Radiation exposure from men after Iodine-125 transperineal seed implantation for prostate cancer and comparison with CT dosimetric data. Australasian Radiology. 2006;50:A59.

Millar JL, Snow R, Royce P, Five-year outcomes after prostate seed implants for prostate cancer in Australia. Brachytherapy. 2007:6(2):107-108.

Millar JL,Zwahlen DR, Andrianopoulos N, et al. Improved prostate cancer control with the use of HDR brachytherapy boost. Brachytherapy. 2008;7:120.

Elliott S, Beaufort C, Millar J, et al. Higher strength seeds for I-125 prostate implants. Brachytherapy. 2008;7:190.

Beaufort C, Tran Y, Stokes D, Millar J et al. Qualitative research to improve patient perception of care: A prostate brachytherapy patient focus group. Brachytherapy. 2008;7:193.

Smith RL, Tran YT, Zwahlen DR, Matheson B, Millar JL, Image fusion of prostate preplan transrectal ultrasound and post 125I-seed implant CT images to improve consistency and accuracy of post-seed implant quality statistics. Brachytherapy. 2009;8(2):116.

Zwahlen DR, Smith RL, Andrianopoulos N, Biostat M, Matheson B, Millar JL, Effect of prostate-specific antigen bounce on outcome in patients treated with permanent 125I-seed prostate brachytherapy. Brachytherapy. 2009;8(2):161.

Zwahlen DR, Andrianopoulos N, Matheson B, Duchesne GM, Millar JL, High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy. 2009;9(1):27-35.

Zwahlen DR, Smith R, Andrianopoulos N, Matheson B, Royce P, Millar JL, Prostate-Specific Antigen Bounce After Permanent Iodine-125 Prostate Brachytherapy – An Australian Analysis. International Journal of Radiation Oncology, Biology, Physics. 2011;79(1):179-187.

From the right ventricle blood goes guidelines in writing a research paper to pulmonary trunk that takes blood away from the heart
Brighton
  • George
  • Brighton
  • Jack from rye
  • Jack
  • Rye
  • Director | Radiation Oncology cancer treatment prostate brachytherapy mac seed peter melbourne
  • Jeremy Millar
  • Director | Radiation Oncology